Becton, Dickinson and Company (NYSE:BDX) Receives Consensus Rating of “Hold” from Analysts

Shares of Becton, Dickinson and Company (NYSE:BDX) have been given a consensus rating of “Hold” by the seventeen ratings firms that are covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, ten have assigned a hold recommendation and six have given a buy recommendation to the company. The average 12 month price objective among analysts that have covered the stock in the last year is $191.6154.

BDX has been the topic of several research reports. Wells Fargo & Company cut their price objective on Becton, Dickinson and Company from $184.00 to $157.00 and set an “equal weight” rating on the stock in a research report on Tuesday, February 10th. Barclays initiated coverage on Becton, Dickinson and Company in a research report on Tuesday, February 10th. They issued an “overweight” rating and a $202.00 price objective on the stock. JPMorgan Chase & Co. cut their price objective on Becton, Dickinson and Company from $190.00 to $175.00 and set a “neutral” rating on the stock in a research report on Tuesday, February 10th. Piper Sandler reissued a “neutral” rating and issued a $170.00 price objective (down from $205.00) on shares of Becton, Dickinson and Company in a research report on Tuesday, February 10th. Finally, Stifel Nicolaus raised their price objective on Becton, Dickinson and Company from $210.00 to $215.00 and gave the company a “buy” rating in a research report on Wednesday, January 7th.

Becton, Dickinson and Company Price Performance

Shares of Becton, Dickinson and Company stock opened at $154.87 on Friday. Becton, Dickinson and Company has a twelve month low of $127.59 and a twelve month high of $187.35. The stock has a market capitalization of $44.10 billion, a P/E ratio of 25.26, a PEG ratio of 11.20 and a beta of 0.29. The company has a current ratio of 1.05, a quick ratio of 0.58 and a debt-to-equity ratio of 0.67. The business’s fifty day moving average price is $173.75 and its 200 day moving average price is $186.01.

Becton, Dickinson and Company (NYSE:BDX) last issued its earnings results on Monday, February 9th. The medical instruments supplier reported $2.91 earnings per share for the quarter, beating analysts’ consensus estimates of $2.81 by $0.10. Becton, Dickinson and Company had a return on equity of 15.76% and a net margin of 8.01%.The firm had revenue of $4.49 billion for the quarter, compared to analysts’ expectations of $5.15 billion. During the same quarter last year, the firm earned $3.43 earnings per share. The firm’s revenue for the quarter was up 1.6% compared to the same quarter last year. Becton, Dickinson and Company has set its FY 2026 guidance at 12.350-12.650 EPS. As a group, research analysts anticipate that Becton, Dickinson and Company will post 14.43 earnings per share for the current year.

Becton, Dickinson and Company declared that its board has approved a stock repurchase plan on Tuesday, January 27th that authorizes the company to repurchase $10.00 million in outstanding shares. This repurchase authorization authorizes the medical instruments supplier to repurchase up to 0% of its shares through open market purchases. Shares repurchase plans are usually a sign that the company’s board of directors believes its stock is undervalued.

Becton, Dickinson and Company Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, March 31st. Shareholders of record on Tuesday, March 10th were given a $1.05 dividend. The ex-dividend date of this dividend was Tuesday, March 10th. This represents a $4.20 annualized dividend and a yield of 2.7%. Becton, Dickinson and Company’s dividend payout ratio (DPR) is 68.52%.

Insider Activity

In other news, EVP Michael David Garrison sold 1,610 shares of Becton, Dickinson and Company stock in a transaction dated Thursday, January 15th. The stock was sold at an average price of $207.46, for a total transaction of $334,010.60. Following the sale, the executive vice president directly owned 12,095 shares of the company’s stock, valued at approximately $2,509,228.70. The trade was a 11.75% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Bertram L. Scott sold 953 shares of Becton, Dickinson and Company stock in a transaction dated Wednesday, February 18th. The stock was sold at an average price of $182.61, for a total value of $174,027.33. Following the sale, the director directly owned 36,763 shares in the company, valued at approximately $6,713,291.43. The trade was a 2.53% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 2,713 shares of company stock worth $536,881 over the last three months. 0.40% of the stock is currently owned by corporate insiders.

Institutional Trading of Becton, Dickinson and Company

Hedge funds and other institutional investors have recently modified their holdings of the business. SOA Wealth Advisors LLC. increased its position in shares of Becton, Dickinson and Company by 256.8% during the third quarter. SOA Wealth Advisors LLC. now owns 132 shares of the medical instruments supplier’s stock worth $25,000 after acquiring an additional 95 shares during the last quarter. Activest Wealth Management increased its position in shares of Becton, Dickinson and Company by 285.3% during the third quarter. Activest Wealth Management now owns 131 shares of the medical instruments supplier’s stock worth $25,000 after acquiring an additional 97 shares during the last quarter. Imprint Wealth LLC purchased a new stake in shares of Becton, Dickinson and Company during the third quarter worth about $25,000. Steph & Co. increased its position in shares of Becton, Dickinson and Company by 95.6% during the fourth quarter. Steph & Co. now owns 133 shares of the medical instruments supplier’s stock worth $26,000 after acquiring an additional 65 shares during the last quarter. Finally, SHP Wealth Management purchased a new stake in shares of Becton, Dickinson and Company during the fourth quarter worth about $26,000. 86.97% of the stock is owned by hedge funds and other institutional investors.

About Becton, Dickinson and Company

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.